Albireo Pharma Inc EBITDA
Mi az Albireo Pharma Inc EBITDA?
A EBITDA az Albireo Pharma Inc - -$112.20
Mi a EBITDA meghatározása?
Az EBITDA a társaság kamat, adózás, értékcsökkenés és amortizáció előtti eredmény, és a társaság nettó eredménye alapján számított számviteli intézkedés, a kamatkiadások, az adók, az értékcsökkenés és az amortizáció levonása előtt, a vállalat jelenlegi működési nyereségességének alapjaként.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA a Health Care szektor a NASDAQ-on cégekben a Albireo Pharma Inc -hoz képest
Mit csinál Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
ebitda -hoz hasonló cégek Albireo Pharma Inc
- Jianzhong Construction Development nak EBITDA -¥113.30 van
- Kadmon Inc nak EBITDA -$113.20 van
- Geron nak EBITDA -$113.06 van
- Pliant Therapeutics nak EBITDA -$112.61 van
- Avalara Inc nak EBITDA -$112.60 van
- Christine International nak EBITDA -¥112.46 van
- Albireo Pharma Inc nak EBITDA -$112.20 van
- Kadmon nak EBITDA -$112.01 van
- Inhibrx nak EBITDA -$111.79 van
- Apollo Future Mobility nak EBITDA -HKD$111.73 van
- Ballard Power Systems nak EBITDA -$111.66 van
- Housing Development and Infrastructure nak EBITDA -₨111.53 van
- ALX Oncology nak EBITDA -$111.40 van